Tech & industry
Rehab technology, assistive tech, equipment and the companies behind them.
- Research30 Oct
A portable saliva biosensor costing just US$2.19 can detect protein levels linked to depression, schizophrenia and bipolar disorder in under three minutes. The device measures brain-derived neurotrophic factor (BDNF), a protein vital for neuron health whose altered levels are associated with several psychiatric conditions. Developed by researchers at the University of São Paulo and Embrapa [...]
- Parkinson's29 Oct
A smartphone platform that helps doctors monitor Parkinson’s symptoms has raised US$5.6m to expand its commercial capacity and advance dementia-monitoring technology. The funding brings total investment to US$11.2m for the clinically validated system, which uses smartphones to track changes in movement, speech and cognition. Kneu Health’s platform includes a tremor measurement tool cleared by the [...]
- Spinal injury28 Oct
ONWARD Medical has raised €50.85m to advance spinal cord stimulation technologies and expand commercialisation of its movement restoration systems. The funding comes from a private placement of 11.3 million new shares at €4.50 per share, extending the company’s cash runway through at least the end of 2026. The Netherlands-based neurotechnology company, which also operates a [...]
- Spinal injury27 Oct
A US$3m grant has been awarded to develop a military-optimised ultrasound guidance system for spinal interventions in armed forces medical settings. The funding will support the creation of a portable device designed for epidural steroid injections at forward-deployed military hospitals, with development expected to take 36 months. Medical technology developer RIVANNA received the Peer-Reviewed Medical [...]
- Multiple sclerosis27 Oct
BioNxt has launched a 15-day dosing optimisation study for its sublingual multiple sclerosis (MS) drug, marking the final step before human bioequivalence testing planned for early 2026. The study represents the last preclinical stage for BNT23001, a thin-film formulation of cladribine designed to dissolve under the tongue for treating MS. Following successful small-animal trials confirming [...]
- Parkinson's27 Oct
A woman with Parkinson’s disease played the clarinet during brain surgery, allowing doctors to observe immediate improvements in her movement. Denise Bacon, 65, from Crowborough in East Sussex, underwent Deep Brain Stimulation (DBS) at King’s College Hospital while awake. Her playing helped surgeons assess the success of the procedure in real time. DBS involves implanting [...]
- Stroke22 Oct
NR Times explores the latest business and pharmaceutical developments in the world of neurorehabilitation. New partnership to distribute of MedRhythms devices for stroke and Parkinson’s Neurorehabilitation company MedRhythms has entered a strategic partnership with Edwards Health Care Services (EHCS), a leading provider of direct-to-home medical products. The partnership enables nationwide distribution of MedRhythms' currently available [...]
- Stroke22 Oct
A new virtual reality training task developed by researchers in Finland shows promise for helping stroke survivors with visuospatial neglect, a condition that affects awareness of one side of space. The VR-based rehabilitation tool combines audiovisual cues with physiotherapy exercises to support recovery. Visuospatial neglect (VSN) affects about 30 per cent of stroke survivors and [...]
- Spinal injury16 Oct
HCA Healthcare UK’s Neuro Rehab Centre sees many patients living with spinal cord injuries. Mandy shares how the team at the centre combines innovative technology with compassionate, patient-centred care to support recovery. Our team here at The Wellington Hospital supports patients at all stages of their journey, from early rehabilitation to ongoing, long-term care. With [...]
- Parkinson's16 Oct
People with Parkinson’s are receiving a new investigational treatment after a successful study demonstrated the therapy’s safety in non-human primates and refined the method for its delivery. Biotechnology company Aspen Neuroscience said it would enrol a third group of participants in its ASPIRO trial after the first four patients safely tolerated the therapy. The Phase [...]

















